Skip to main navigation
Skip to search
Skip to main content
WashU Research Profiles Home
Help & FAQ
Link opens in a new tab
Search content at WashU Research Profiles
Home
Profiles
Research units
Research output
Economic evaluation of plerixafor for stem cell mobilization
Steven M. Kymes
,
Iskra Pusic
, Dennis L. Lambert
, Martin Gregory
, Kenneth R. Carson
,
John F. DiPersio
Institute of Clinical and Translational Sciences (ICTS)
Siteman Cancer Center
Bursky Center for Human Immunology and Immunotherapy
Department of Medicine
Division of Oncology
Center of Regenerative Medicine
Research output
:
Contribution to journal
›
Article
›
peer-review
30
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Economic evaluation of plerixafor for stem cell mobilization'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Stem Cell Mobilization
100%
Economic Evaluation
100%
Plerixafor
100%
Lymphoma Patients
66%
Granulocyte Colony-stimulating Factor (G-CSF)
66%
Diffuse Large B-cell Lymphoma (DLBCL)
66%
Allogeneic Peripheral Blood Stem Cell Transplantation
50%
Non-Hodgkin Lymphoma
33%
Incremental Cost-effectiveness Ratio
33%
Quality-adjusted Life Years
33%
Cost-effectiveness
16%
Failure Rate
16%
Phase I Study
16%
Medicare
16%
Process of Care
16%
University of Washington
16%
Sensitivity Analysis
16%
Remaining Lifetime
16%
Clinically Significant Change
16%
Markov Model
16%
Heavily Pretreated
16%
High-dose Chemotherapy
16%
Mobilization Regimen
16%
Cost-utility
16%
Lifetime Cost
16%
Expected Lifetime
16%
Microsimulation
16%
Utility Evaluation
16%
Preferred Treatment
16%
Relapsed/refractory Hodgkin Lymphoma
16%
Medicine and Dentistry
Health Care Cost
100%
Plerixafor
100%
Stem Cell Mobilization
100%
Diffuse Large B-Cell Lymphoma
66%
Granulocyte Colony Stimulating Factor
66%
Non-Hodgkin Lymphoma
50%
Autologous Peripheral Blood Stem Cell Transplantation
50%
Lifespan
33%
Quality Adjusted Life Year
33%
Medicare
16%
High Dose Chemotherapy
16%